VolitionRx

Edison Investment Research is terminating coverage on VolitionRx (VNRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Thematics

Latest

From gold to gold miners: Extracting higher returns in the current bull run

Listed companies can no longer afford to ignore retail investors

Inside the mind of investors: Oberon Investments

Audiovisual

Latest

The Law Debenture Corporation in 60 seconds

Team Internet – executive interview

Take on Trusts – March 2025

About Edison

About Edison

Careers

VolitionRx (NYSE: VNRX)

Latest Insights

VolitionRx — Building real-world Nu.Q NETs sepsis data

Volition webinar: Nu.Q NETs data insights

VolitionRx webinar: Unravelling the web of NETs in sepsis … Part II

VolitionRx — Snaring sepsis, with early NETs detection

Sector

VolitionRx — New platform format; more proof-of-concept data

VolitionRx — Data with product-grade assays expected soon

VolitionRx — Nu.Q lung cancer test development accelerates

VolitionRx — Multiple partnerships enable diversification

VolitionRx — Platform upgrades and busy 2019

VolitionRx — Shifts in US CRC screening; major catalysts in H2

VolitionRx — Results from asymptomatic CRC trial reported

VolitionRx — Big EU trials on deck

VolitionRx — 13,500-person prospective US trial on deck

VolitionRx — Gaining more evidence

VolitionRx — Something innovative in the state of Denmark

VolitionRx — Update 6 January 2017

VolitionRx — Update 23 September 2016

VolitionRx — Update 1 April 2016

VolitionRx — Update 6 January 2016